Table 4.
Summary of evidence for the use of immunoglobulin replacement therapy in CLL.
| Reference | Number of patients | Number of patients in advanced stage* | Type of study | Dose IVIG/schedule | Study duration (months) | Infection rate during IVIG administration |
|---|---|---|---|---|---|---|
| Cooperative group (206) | 81 | 32 (39.5%) | Controlled, randomized double-blind | 400 mg/kg/ 21 days | 12 | Decreased |
| Jurlander et al. (207) | 15 | 8 (53.3%) | Not controlled, pilot | 10 g/28 days | 12 (mean time) | Decreased |
| Chapel et al. (208) | 34 | 15 (44.1%) | Controlled, randomized double-blind | 250 mg/kg vs. 500 mg/kg/28 days | 12 | Decreased |
| Sklenar et al. (209) | 31 | 2 (6.4%) | Dose-finding | 100–800 mg/kg/ 21 days | 4.5 | Decreased |
| Griffiths et al. (210) | 10 | 3 (30%) | Controlled, randomized double-blind | 400 mg/kg 21 days | 12 | Decreased |
| Broughton et al. (211) | 42 | 15 (35.7%) | Randomized | 18 g/21 days | 12 | Decreased |
| Molica et al. (212) | 30 | 25 (83.3%) | Randomized, crossover | 300 mg/kg/28 days | 6 or 12 | Decreased |
*
Binet stage C or Rai III-IV.